Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failure

Effect of Empagliflozin on clinical and echocardiographic parameters in non diabetic patient with reduced LVEF heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210809052117N1

Enrollment

Registered

2022-06-25

Start date

2022-06-28

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failre with reduced EF(ejection fraction). Heart failure

Interventions

Intervention 1: Intervention group: patient known case of heart failure, nondiabetic,18_80yr with EF 40% or less and on standard HF treatment that confer to EMAM HOSSEIN cardiovascular Clinic

they receive empagliflozin 10 mg, daily. Intervention 2: Control group: patient known case of heart failure, nondiabetic,18_80yr with EF 40% or less and on standard HF treatment that confer to EMAM H

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age: 18 yr_80 yr Heart failure with reduced EF <40% Nondiabetic Stable symptom and therapy for heart failure

Exclusion criteria

Exclusion criteria: Cardiovascular event, admission for cardiovascular or renal complications within last 3 months Cancer or life-threatening condition Estimated GFR < 45 ml/min/m2 Systolic blood pressure < 90mmhg Pregnancy or lactating women

Design outcomes

Primary

Measure	Time frame
Echocardiography index. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Echocardiography.;Quality of life. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Kansas questionnaire.;Physical activity. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: NYHA Class and 6-MWT.	—

Measure

Time frame

Echocardiography index. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Echocardiography.;Quality of life. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Kansas questionnaire.;Physical activity. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: NYHA Class and 6-MWT.

—

Secondary

Measure	Time frame
Renal function. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Creatinine measuring and computing Glomerular Filtration Rate.;Cardiac mortality. Timepoint: During the study. Method of measurement: Follow up.;Myocardial Infurction. Timepoint: During the study. Method of measurement: Follow up.;Duration of hospitalization for cardiac causes. Timepoint: During the study. Method of measurement: Follow up.	—

Measure

Time frame

Renal function. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Creatinine measuring and computing Glomerular Filtration Rate.;Cardiac mortality. Timepoint: During the study. Method of measurement: Follow up.;Myocardial Infurction. Timepoint: During the study. Method of measurement: Follow up.;Duration of hospitalization for cardiac causes. Timepoint: During the study. Method of measurement: Follow up.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasim Arabzadeh

Shahid Beheshti University of Medical Sciences

nasimarabbreeze@gmail.com+98 21 23871

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026